[ibd-display-video id=2881825 width=50 float=left autostart=true] IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves. See if Supernus Pharmaceuticals can continue to show renewed price strength and clear that threshold.
Supernus Pharmaceuticals is building a consolidation with a 50.14 buy point . See if it can break out in volume at least 40% above average.
The company posted -28% EPS growth in the latest quarterly report. Sales gains came in at 42%.
The company earns the No. 49 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Vertex Pharmaceuticals ( VRTX ) and Sucampo Pharmaceuticals ( SCMP ) are among the top 5 highly rated stocks within the group.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.